Insider Transactions in Q1 2025 at Enanta Pharmaceuticals Inc (ENTA)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 12
2025
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,326
-7.64%
|
$16,630
$5.59 P/Share
|
|
Feb 12
2025
|
Brendan Luu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+14.69%
|
-
|
|
Feb 12
2025
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,324
-1.14%
|
$21,620
$5.59 P/Share
|
|
Feb 12
2025
|
Yat Sun Or Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,750
+2.51%
|
-
|
|
Feb 12
2025
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,861
-10.34%
|
$14,305
$5.59 P/Share
|
|
Feb 12
2025
|
Scott T. Rottinghaus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,750
+26.06%
|
-
|
|
Feb 12
2025
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,326
-9.04%
|
$16,630
$5.59 P/Share
|
|
Feb 12
2025
|
Tara Lynn Kieffer Chief Product Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+16.93%
|
-
|
|
Feb 12
2025
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,484
-0.86%
|
$37,420
$5.59 P/Share
|
|
Feb 12
2025
|
Jay R. Luly President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+2.84%
|
-
|
|
Feb 12
2025
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,326
-3.35%
|
$16,630
$5.59 P/Share
|
|
Feb 12
2025
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+7.03%
|
-
|
|
Feb 12
2025
|
Jay R. Luly President and CEO |
BUY
Open market or private purchase
|
Direct |
45,000
+5.05%
|
$225,000
$5.69 P/Share
|